MyCural Therapeutics is developing a cancer therapy for patients with aggressive high-risk tumors. The MYC oncoprotein is the main driver of more than 50% of all cancers, which leads to aggressive tumors, resistance to cancer treatment and poor prognosis. There are currently no specific drugs against MYC. Mycural Therapeutics has patented effective, selective small molecule MYC inhibitors that can be developed into drugs and cancer therapy for patients with intractable MYC-driven tumors. This could revolutionize the treatment of patients with currently non curable tumors in late stages.